Ignite Creation Date:
2024-05-05 @ 4:38 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00282555
Status:
SUSPENDED
Last Update Posted:
2008-03-19
First Post:
2006-01-25
Brief Title:
Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis
Sponsor:
STEBA France
Organization:
STEBA France
Study Overview
Official Title:
Assessment of the Healing Rate of Erosive or Ulcerative Esophagitis After Two and Four Weeks of Treatment With S-Tenatoprazole-Na STU-Na 15 mg 30 mg 60 mg 90 mg and Esomeprazole 40 mg A Multicenter Randomized Double-Blind Parallel Group Study
Status:
SUSPENDED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
STU-Na belongs to the proton pump inhibitors PPI a group of drugs that reduce gastric acidity PPI are used to treat acid related diseases like erosive or ulcerative esophagitis This trial aims to find out the therapeutic dose of STU-Na required for healing patients with erosive or ulcerative esophagitis One of four dosages of STU-Na 15 mg 30 mg 60 mg or 90 mg daily or Esomeprazole 40 mg daily an already marketed PPI will be given to patients The attribution to one of the 5 treatment groups will be by chance Neither the patient nor the study physician will know which treatment is administered to the patient
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None